These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2039863)

  • 1. Chemotherapy of acute myelogenous leukaemia.
    Marie JP; Zittoun R
    Baillieres Clin Haematol; 1991 Jan; 4(1):97-113. PubMed ID: 2039863
    [No Abstract]   [Full Text] [Related]  

  • 2. Intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia.
    Ferrant A; Doyen C; Bosly A; Delannoy A; Cornu G; Michaux JL
    Br J Haematol; 1987 Nov; 67(3):375. PubMed ID: 3479998
    [No Abstract]   [Full Text] [Related]  

  • 3. [Role of double induction in the treatment of acute myeloblastic leukemia in the adult: intermediate results of protocol LAM90].
    Castaigne S; Archimbaud E; Fenaux P; Bordessoule D; Tilly H; Simon M; Dupriez B; Auzanneau G; Legros M; Tertian G
    Nouv Rev Fr Hematol (1978); 1994 Jul; 36 Suppl 2():S139-40. PubMed ID: 7971262
    [No Abstract]   [Full Text] [Related]  

  • 4. Differentiation induction therapy of acute myelogenous leukaemias.
    Hassan HT
    Haematologia (Budap); 1988; 21(3):141-50. PubMed ID: 3053358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of polycythemia vera after chemotherapy-induced remission of acute myeloid leukemia: a case report.
    Belotti A; Doni E; Elli E; Rossi V; Pioltelli P; Pogliani EM
    Acta Haematol; 2011; 126(1):52-3. PubMed ID: 21454967
    [No Abstract]   [Full Text] [Related]  

  • 6. Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis.
    Berneman ZN; Anguille S; Van Marck V; Schroyens WA; Van Tendeloo VF
    Br J Haematol; 2010 Apr; 149(1):152-5. PubMed ID: 19995392
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
    Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
    Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukaemia.
    Short NJ; Rytting ME; Cortes JE
    Lancet; 2018 Aug; 392(10147):593-606. PubMed ID: 30078459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
    Lun Y; Yang JJ; Wu Y
    J Clin Pharm Ther; 2017 Dec; 42(6):786-789. PubMed ID: 28646565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy in acute myeloid leukaemia: origins and emerging directions.
    Upadhyay VA; Fathi AT
    Curr Opin Hematol; 2018 Mar; 25(2):67-74. PubMed ID: 29337707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
    Peters WG; Willemze R; Colly LP
    Eur J Haematol; 1988 Mar; 40(3):198-204. PubMed ID: 3162718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mutant IDH1 in acute myeloid leukaemia.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638561
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.
    Jahic A; Iljazovic E; Hasic S; Arnautovic AC; Sabitovic D; Mesanovic S; Sahovic H; Simendic V
    Med Arch; 2017 Feb; 71(1):20-24. PubMed ID: 28428668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
    Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E
    Br J Haematol; 2007 Aug; 138(4):555-7. PubMed ID: 17593249
    [No Abstract]   [Full Text] [Related]  

  • 15. Testicular relapse in acute myelogenous leukaemia after 3 1/2 years of complete remission.
    Russo A; Vasquez E; Russo G; Schilirò G
    Acta Haematol; 1981; 65(2):131-3. PubMed ID: 6785960
    [No Abstract]   [Full Text] [Related]  

  • 16. Low-dose combination remission induction therapy for acute myeloid leukaemia in elderly patients--a pilot study.
    Manoharan A
    Aust N Z J Med; 1992 Dec; 22(6):710-1. PubMed ID: 1489302
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategies for acute myelogenous leukemia.
    Gale RP; Butturini A
    Bone Marrow Transplant; 1991; 7 Suppl 2():58. PubMed ID: 1878721
    [No Abstract]   [Full Text] [Related]  

  • 18. Conception and congenital abnormalities after chemotherapy of acute myelogenous leukaemia in two men.
    Russell JA; Powles RL; Oliver RT
    Br Med J; 1976 Jun; 1(6024):1508. PubMed ID: 1064461
    [No Abstract]   [Full Text] [Related]  

  • 19. Early discharge from hospital after consolidation chemotherapy in acute myeloid leukemia in remission: febrile neutropenic episodes and their outcome in a resource poor setting.
    Naithani R; Kumar R; Mahapatra M; Agrawal N; Mishra P
    Haematologica; 2008 Sep; 93(9):1416-8. PubMed ID: 18603560
    [No Abstract]   [Full Text] [Related]  

  • 20. Intensive chemotherapy for acute myelogenous leukemia.
    Gale RP; Foon KA; Cline MJ; Zighelboim J
    Ann Intern Med; 1981 Jun; 94(6):753-7. PubMed ID: 6940466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.